Free tool
FAERS Monitor: Ofev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205832 or its brand name (Ofev, Nintedanib Esylate). Reports on generic versions are filed under their own applications.
Reports
32,515
Serious
22,042
68% of reports
Hospitalization
10,897
Death reported
6,449
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea10,539
- nausea4,818
- dyspnoea4,179
- cough3,397
- death3,386
- decreased appetite3,188
- weight decreased3,173
- fatigue3,033
- vomiting2,828
- idiopathic pulmonary fibrosis2,209
- headache2,071
- constipation2,053
- abdominal pain upper1,925
- asthenia1,760
- abdominal discomfort1,683
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 36 |
| 2015 | 960 |
| 2016 | 1,298 |
| 2017 | 1,463 |
| 2018 | 1,924 |
| 2019 | 2,057 |
| 2020 | 2,461 |
| 2021 | 3,012 |
| 2022 | 3,745 |
| 2023 | 3,790 |
| 2024 | 4,276 |
| 2025 | 3,898 |
| 2026 | 3,591 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,021,644 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| idiopathic pulmonary fibrosisSignal | 2,209 | 816.6 | 767.6 | 794,911 |
| diarrhoeaSignal | 10,539 | 10.7 | 10.6 | 94,250 |
| decreased appetiteSignal | 3,188 | 9.0 | 8.7 | 22,564 |
| coughSignal | 3,397 | 7.9 | 7.7 | 20,556 |
| weight decreasedSignal | 3,173 | 7.4 | 7.2 | 17,670 |
| abdominal discomfortSignal | 1,683 | 6.5 | 6.2 | 7,885 |
| constipationSignal | 2,053 | 6.1 | 5.9 | 8,833 |
| abdominal pain upperSignal | 1,925 | 6.1 | 5.8 | 8,198 |
| dyspnoeaSignal | 4,179 | 4.8 | 4.7 | 12,834 |
| nauseaSignal | 4,818 | 4.0 | 3.9 | 10,987 |
| vomitingSignal | 2,828 | 3.9 | 3.8 | 6,220 |
| astheniaSignal | 1,760 | 3.0 | 2.9 | 2,435 |
| deathSignal | 3,386 | 2.5 | 2.5 | 3,307 |
| fatigueSignal | 3,033 | 2.5 | 2.4 | 2,890 |
| headacheSignal | 2,071 | 2.1 | 2.1 | 1,292 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.